PFE Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

16.93B

-4.67%

0.562

-10.86%

13.98B

+1.94%

0.751

-18.38%

14.50B

-1.04%

0.733

-6.06%

Estimates Revision

The market is revising Downward the revenue expectations for Pfizer Inc. (PFE) for FY2025, with the revenue forecasts being adjusted by -1.78% over the past three months. During the same period, the stock price has changed by -4.26%.

Revenue Estimates for FY2025

Revise Downward

-1.78%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+0.99%

In Past 3 Month

Stock Price

Go Down

-4.26%

In Past 3 Month

15 Analyst Rating

Wall Street analysts forecast PFE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PFE is 29.08 USD with a low forecast of 24.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

10 Hold

1 Sell

Hold

Current: 0.000

Low

24.00

Averages

29.08

High

34.00

Current: 0.000

Low

24.00

Averages

29.08

High

34.00

UBS

Neutral

initiated

$25

2026-01-06

New

Reason

UBS

Price Target

$25

2026-01-06

New

initiated

Neutral

Reason

UBS assumed coverage of Pfizer with a Neutral rating and $25 price target. The firm noted a backdrop of continued revenue uncertainty with $15B-$20B in revenues from key drugs losing patient exclusivity over the coming roughly three years. Though the firm is positive on the recent MTSR obesity deal, Pfizer needs to do more to offset 2028 LOE risk, the analyst tells investors in a research note.

BofA

Jason Gerberry

Neutral

downgrade

$28 -> $27

2025-12-16

Reason

BofA

Jason Gerberry

Price Target

$28 -> $27

2025-12-16

downgrade

Neutral

Reason

BofA analyst Jason Gerberry lowered the firm's price target on Pfizer to $27 from $28 and keeps a Neutral rating on the shares after the company "notably called out" faster COVID-19 product erosion relative to prior guidance as part of its 2026 outlook call. The firm, which "modestly" reduced its 2026 Pfizer sales and EPS estimates and its FY27 EPS estimate following the guidance call, looks to planned obesity data updates from the Metsera acquisition to better understand the company's potential obesity differentiation.

BofA

Jason Gerberry

Neutral

downgrade

$29 -> $28

2025-12-15

Reason

BofA

Jason Gerberry

Price Target

$29 -> $28

2025-12-15

downgrade

Neutral

Reason

BofA analyst Jason Gerberry lowered the firm's price target on Pfizer to $28 from $29 and keeps a Neutral rating on the shares. The firm, which struggles to see a rerating catalyst as the company works through its multi-year loss of exclusivity period, is shifting its valuation basis to its FY27 EPS estimate.

Morgan Stanley

Equal Weight

downgrade

$32 -> $28

2025-12-12

Reason

Morgan Stanley

Price Target

$32 -> $28

2025-12-12

downgrade

Equal Weight

Reason

Morgan Stanley lowered the firm's price target on Pfizer to $28 from $32 and keeps an Equal Weight rating on the shares. The firm expects many of the policy overhangs that dominated the biopharma conversation this year to wane in 2026, bringing the focus back to fundamentals, the analyst tells investors in a 2026 outlook note for the group.

HSBC

Rajesh Kumar

Buy

maintain

$28 -> $29

2025-12-10

Reason

HSBC

Rajesh Kumar

Price Target

$28 -> $29

2025-12-10

maintain

Buy

Reason

HSBC analyst Rajesh Kumar raised the firm's price target on Pfizer to $29 from $28 and keeps a Buy rating on the shares as part of a 2026 outlook for the pharma group. The firm believes the sector is well positioned to outperform in 2026, "even more so if AI panic kicks in." HSBC's preferred stocks are "growth bucket ideas," but says "fallen angels and value could work as well."

Guggenheim

Buy

maintain

$33 -> $35

2025-11-24

Reason

Guggenheim

Price Target

$33 -> $35

2025-11-24

maintain

Buy

Reason

Guggenheim raised the firm's price target on Pfizer to $35 from $33 and keeps a Buy rating on the shares. Pfizer's acquisition of Metsera is "a wise strategic move" to gain traction in the rapidly growing obesity market following recent setbacks with the company's internal oral GLP-1 programs, the analyst tells investors.

Valuation Metrics

The current forward P/E ratio for Pfizer Inc (PFE.N) is 8.63, compared to its 5-year average forward P/E of 12.23. For a more detailed relative valuation and DCF analysis to assess Pfizer Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

5Y Average PE

12.23

Current PE

8.63

Overvalued PE

18.56

Undervalued PE

5.90

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

5Y Average EV/EBITDA

9.39

Current EV/EBITDA

7.04

Overvalued EV/EBITDA

12.85

Undervalued EV/EBITDA

5.92

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

2.85

Current PS

2.33

Overvalued PS

3.37

Undervalued PS

2.34

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

PFE News & Events

Events Timeline

No data

News

9.5

01-05NASDAQ.COM

PinnedPfizer Maintains Nearly 7% Dividend Yield Amidst Revenue Decline and R&D Prospects

7.0

19:40 PMBusinesswire

Pfizer Faces Lawsuit Over Depo-Provera Risks, First Trial Set for December 2026

7.0

19:23 PMNewsfilter

Pfizer Faces Over 2,100 Lawsuits as FDA Approves Brain Tumor Warning

People Also Watch

Frequently Asked Questions

What is Pfizer Inc (PFE) stock price today?

The current price of PFE is 25.15 USD — it has decreased -1.1 % in the last trading day.

What is Pfizer Inc (PFE)'s business?

Pfizer Inc. is a research-based, global biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. Its Biopharma segment includes the Pfizer U.S. Commercial Division, and the Pfizer International Commercial Division. Its product categories include oncology, primary care and specialty care. Its oncology products include Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna. Its primary care products include Eliquis, Nurtec ODT/Vydura, Zavzpret, the Prevnar family, Comirnaty, Abrysvo, FSME/IMMUN-TicoVac, Nimenrix, Trumenba, and Paxlovid. Its specialty care products include Xeljanz, Enbrel (outside the United States and Canada), Inflectra, Abrilada, Cibinqo, Litfulo, Eucrisa, Velsipity, the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, Hympavzi, Sulperazon, Zavicefta, Octagam and others.

What is the price predicton of PFE Stock?

What is Pfizer Inc (PFE)'s revenue for the last quarter?

Pfizer Inc revenue for the last quarter amounts to 16.65B USD, decreased -5.92 % YoY.

What is Pfizer Inc (PFE)'s earnings per share (EPS) for the last quarter?

Pfizer Inc. EPS for the last quarter amounts to 0.62 USD, decreased -20.51 % YoY.

What changes have occurred in the market's expectations for Pfizer Inc (PFE)'s fundamentals?

How many employees does Pfizer Inc (PFE). have?

Pfizer Inc (PFE) has 81000 emplpoyees as of January 07 2026.

What is Pfizer Inc (PFE) market cap?

Today PFE has the market capitalization of 144.59B USD.

PFE

Overview

Forecast

Valuation

Earnings

PFE

Overview

Forecast

Valuation

Earnings

Market Estimates

Valuation Metrics

Forward PE

Forward EV/EBITDA

Forward PS

Financials

Trading Trends

PFE News & Events

Events Timeline

No data

News

People Also Watch

Frequently Asked Questions

What is Pfizer Inc (PFE) stock price today?

What is Pfizer Inc (PFE)'s business?

What is the price predicton of PFE Stock?

What is Pfizer Inc (PFE)'s revenue for the last quarter?

What is Pfizer Inc (PFE)'s earnings per share (EPS) for the last quarter?

What changes have occurred in the market's expectations for Pfizer Inc (PFE)'s fundamentals?

How many employees does Pfizer Inc (PFE). have?

What is Pfizer Inc (PFE) market cap?